Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Shares of pharmaceutical giant Eli Lilly (NYSE:LLY) edged down 1.2% in premarket trading following announcements from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback